Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Zidebactam is a diazabicyclooctane beta-lactamase inhibitor and PBP2-binding antibacterial, used only with cefepime, indicated for complicated urinary tract infections including pyelonephritis caused by susceptible Gram-negative pathogens. Zidebactam is a diazabicyclooctane that acts both as a beta-lactamase inhibitor and as an antibacterial in its own right, selectively binding penicillin-binding protein 2.
- Mechanism
- Curator reviewed · 4 references
Zidebactam is a beta-lactamase inhibitor and non-beta-lactam antibacterial that selectively inhibits penicillin-binding protein-2 (PBP2). Together with cefepime, which primarily targets PBP3 in Gram-negative bacterial pathogens, zidebactam binds multiple penicillin-binding proteins, leading to bacterial killing. This synergy occurs even in the presence of beta-lactamases, including metallo-beta-lactamases, which zidebactam does not inhibit, and other non-enzymatic cefepime resistance mechanisms such as hyper-efflux and downregulation of outer membrane porin channels. As a non-beta-lactam, zidebactam is less susceptible to degradation by beta-lactamases, and it shows in vitro activity against Ambler Class A (SHV, TEM, CTX-M and KPC) and Class C (CMY) beta-lactamases.
- Primary indication
- Zidebactam in combination with cefepime is indicated for the treatment of adult patients with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae...Curator reviewed · 2 structured indications
- Formula / weight
- C13H21N5O7S · 391.4 g/mol (avg)
- First approval
- United States, 2026
- Code names
- WCK-5107
- Brand names
- Zaynich
Resolves to
YCZPXRQPDCXTIO-BBBLOLIVSA-NSMILESOS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NNC(=O)[C@@H]2CCCNC2)C1=OWhat you can answer from here — as of November 03, 2026
Which drugs share a target with Zidebactam, and which of those have an active Phase 3 trial?